

# INDUSTRY NEWS

## MAQUET CRITICAL CARE RECEIVES FDA 510(K) CLEARANCE FOR MAJOR ADVANCE IN MECHANICAL VENTILATION

### MAQUET

Bridgewater, NJ - February 26, 2007 - MAQUET Critical Care announces that they have received FDA 510(k) clearance to its breakthrough NAVA (Neurally Adjusted Ventilatory Assist) technology for optional use with the company's SERVO-i ventilator. The SERVO-i ventilator with NAVA option is intended for treatment and monitoring of all patients, neonatal, pediatric, and adults who require mechanical ventilation.

The NAVA technology detects respiratory signals sent from the brain to the diaphragm (in cases where the brain-to-diaphragm electrical signal is intact) and transmits those signals to the SERVO-i ventilator. By enabling the respiratory signals from the patient's brain to control ventilator function, NAVA technology results in unprecedented coordination between diaphragmatic activation and ventilatory support throughout the breathing cycle.

## REBECCA W. RIMEL, PRESIDENT AND CEO OF THE PEW CHARITABLE TRUSTS, JOINS VIASYS HEALTHCARE'S B.O.D.

### VIASYS<sup>TM</sup> HEALTHCARE *Excellence For Life*

Randy H. Thurman, Chairman & CEO of VIASYS Healthcare Inc. (NYSE:VAS), released the following statement: "I am extremely pleased to announce that Rebecca W. Rimel, President and Chief Executive Officer of The Pew Charitable Trusts has joined the Board of Directors of VIASYS Healthcare Inc. Ms. Rimel's proven leadership combined with her healthcare background will add tremendous value to our board and to the strategic direction of VIASYS."

Ms. Rimel began her tenure at The Pew Charitable Trusts in 1983 as health program manager. She became executive director in 1988 and accepted her current position as President and CEO in 1994. Prior to joining The Pew Charitable Trusts, Ms. Rimel built an exemplary career in health care, specifically in the field of nursing. From 1981 through 1983, she was assistant professor in the Department of Neurosurgery at the University of Virginia Hospital, making her the first nurse to hold a faculty position in the University's medical school. Along with additional teaching and practitioner positions at the University of Virginia Hospital, she was head nurse of the medical center's emergency department.

Ms. Rimel also brings exceptional board experience to VIASYS. In addition to being a member of the board of The Pew Charitable Trusts, she serves on the boards of Deutsche Asset Management/DWS Scudder Funds and the Thomas Jefferson Foundation, and is a member of the Executive Committee of the Greater Philadelphia Chamber of Commerce. Ms. Rimel received her Bachelor of Science, with distinction, from the University of Virginia School of Nursing in 1973, and earned a Master of Business Administration from James Madison University in 1983.

## GE TO ACQUIRE ABBOTT'S IN VITRO AND POINT-OF-CARE DIAGNOSTICS BUSINESSES FOR \$8.13 BILLION



General Electric Company and Abbott, a global leader in medical diagnostic instruments and tests, announced that they have entered into a definitive agreement for GE to acquire Abbott's primary in vitro diagnostics businesses and Abbott Point-of-Care diagnostics business (formerly known as i-STAT) for \$8.13 billion in cash. Abbott's Molecular Diagnostics and Diabetes Care businesses are not part of the transaction and will remain part of Abbott. The addition of two of Abbott's core laboratory diagnostics businesses will broaden GE Healthcare's diagnostic offerings. Abbott's in vitro diagnostic (in vitro diagnostics test blood or urine samples to diagnose disease or other conditions) complement GE's existing positions in in vivo diagnostic imaging systems (in vivo imaging uses X-ray, magnetic resonance, ultrasound or other imaging procedures to look at what is in the body to diagnose disease), as well as its molecular imaging, information technology, and patient monitoring capabilities across the complete healthcare continuum. The transaction, which is subject to regulatory approvals and other customary conditions, has been approved by the Boards of Directors of Abbott and GE and is targeted to close in the first half of 2007.

## PORTABLE SOMNOSCREEN SLEEP-MONITORING SYSTEM (SOMNOSCREEN PSG) APPROVED FOR U.S. SALES

### SOMNO medics

Somnomedics (USA) LLC has received U.S. Food and Drug Administration approval to market its miniaturized Somnoscreen sleep disorder diagnostic system in the United States.

"The Somnoscreen is the fastest-growing medical device of its kind in Europe and is now expanding to the North American marketplace," said Allan F. Brack, Somnomedics vice president of sales for the Americas. Somnomedics (USA) LLC is the North American marketing arm of Somnomedics Grr.bH of Kist, Germany. The palm-sized Somnoscreen is the smallest, full-featured, sleep-monitoring system available today. It is a completely portable Polysomnograph that provides unparalleled mobility for the patient and the sleep practitioner. The light, fully contained Somnoscreen wirelessly transmits data to the practitioner's PC, where it can be monitored in real time or stored for later evaluation. The 28-channel wireless transmission allows the patient to sleep more normally, using the bathroom when necessary and avoiding the anxiety of being tethered to a bed with wires and electrodes. With the addition of the mobile, digital video and audio option, with built-in infrared light source and radio transmitter, the patient can be monitored without multiple cabling. The Somnoscreen is available in a variety of configurations from a simple screener to a full sleep-laboratory system with telemetry and video. The modular design can be upgraded at any time. The Somnoscreen operates on a Li-ion battery with no memory effect, that provides 24 hours of continuous recording on a high-capacity 1 GB flash card. Its small radio module transfers data up to 100 meters and up to 36 systems can be used simultaneously.

For more information on the Somnoscreen, or if interested in being a distributor. Call Somnomedics U.S. office in Cooper City, Fla., at 954-646-3734 or go online to [www.somnomedics.de/usa](http://www.somnomedics.de/usa).

## SEQUAL'S ECLIPSE HONORED AS SAN DIEGO'S "OUTSTANDING MANUFACTURING ENGINEERING PROJECT AWARD"



SeQual Technologies Inc., received the Outstanding Manufacturing Engineering Project Award from the San Diego County Engineering Council for its introduction of the Eclipse(R) Oxygen System. The award was presented on Friday, February 23 at the Joan Kroc Institute for Peace and Justice on the University of San Diego campus as part of the 55th Annual National Engineers Week.

The Eclipse is the only oxygen concentrator on the market that is portable yet also powerful enough to supply adequate oxygen during sleep - up to 3 continuous-flow liters per minute. This allows previously home-bound patients to have a lifestyle of freedom and independence, freeing them from 50-pound stationary home oxygen concentrators and out-dated compressed gas cylinder technology. Developed over five years at a cost of \$12 million, the Eclipse weighs 17 pounds, has a retractable handle and wheels for mobility, and is about the size of a student's backpack. The Outstanding Manufacturing Engineering Project Award recognizes an outstanding project brought to fulfillment within the past five years through design and production that benefits the general public. To be eligible, the project must have been constructed or produced in San Diego County. The National Engineering Week San Diego Committee, comprised of representatives from local engineering societies and engineering schools, judges the nominations.

## BLOOD GAS CALIBRATION VERIFICATION CONTROLS



RNA Medical®, division of Bionostics, Inc., Devens, MA, announces CVC 123, Calibration Verification Controls for use with blood gas, electrolyte, and metabolite analyzers, is now assayed for IL GEM® Premier™ 3000, Bayer® 400 Series, and Radiometer ABL® 800 Series analyzers. CVC 123 is used to confirm the calibration and linearity of blood gas systems measuring pH, pCO<sub>2</sub>, pO<sub>2</sub>, sodium, potassium, chloride, ionized calcium, ionized magnesium, glucose, and lactate. Provided in 5 levels, it is packaged in kits containing 4 ampuls of each level. In addition to US availability, CVC 123 is distributed in Canada through Thermo Fisher Scientific. 800-533-6162. [www.RNAMedical.com](http://www.RNAMedical.com).